OBI Pharma forms strategic partnership with GlyTech to broaden its reach and capabilities

OBI Pharma, a clinical-stage oncology company, has entered into a Marketing Agreement and Material Transfer Agreement with GlyTech, a Japan-based manufacturer of glycans. Under the agreement, OBI grants GlyTech rights to market and promote its GlycOBI ADC enabling technologies in Japan. GlyTech will also be a key supplier of glycans in Japan. OBI will transfer cutting-edge materials to GlyTech for research on efficient glycan production for ADCs. The CEO of OBI Pharma, Heidi Wang, stated that the company is excited to collaborate with GlyTech to expand its novel GlycOBI ADC technologies to potential partners in Japan. Hiroaki Asai, CEO of GlyTech, added that GlyTech is pleased to support the development of GlycOBI ADC technologies with high-quality human glycans. The agreements are expected to contribute to the advancement of ADCs and enhance the supply of high-quality glycans for their development.